It’s only fair to share… Ziftomenib CAS 2134675-36-6 4MOD1F4ENC, KO 539 717.9 g/mol, C33H42F3N9O2S2 APPROVALS 2025, FDA 2025, 11/13/2025, Komzifti 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options Ziftomenib, sold under the brand name Komzifti, is an anti-cancer medication used for the treatment …